^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SIRPA antagonist

    Related drugs:
    1m
    A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone (clinicaltrials.gov)
    P1, N=90, Recruiting, Boehringer Ingelheim | Trial completion date: Mar 2028 --> Jul 2027 | Trial primary completion date: Jul 2027 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • BI 770371
    2ms
    A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes (clinicaltrials.gov)
    P1, N=56, Terminated, Bristol-Myers Squibb | Completed --> Terminated; Business objectives have changed
    Trial termination
    |
    Venclexta (venetoclax) • azacitidine • anzurstobart (BMS-986351)
    3ms
    Dual STING activation and CD47/SIRPα blockade via chitooligosaccharide-based nanoparticles to amplify antitumor immunity. (PubMed, J Control Release)
    To further counter immune evasion, we encapsulated the CD47/SIRPα inhibitor RRX-001 into reactive oxygen species (ROS)-responsive carriers, yielding RRX@RCD...In CT26 tumor-bearing mice, RRX@RCD achieved superior tumor regression, doubled median survival. Overall, RRX@RCD synchronizes innate and adaptive immune activation, offering a safe and potent nanomedicine strategy for durable antitumor immunity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STING (stimulator of interferon response cGAMP interactor 1) • SIRPA (Signal Regulatory Protein Alpha)
    |
    nibrozetone (RRx-001)
    4ms
    A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BI 770371
    4ms
    A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
    P1, N=13, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    ezabenlimab (BI 754091) • BI 765063 • BI 770371
    4ms
    A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov)
    P2, N=24, Recruiting, Boehringer Ingelheim | Active, not recruiting --> Recruiting
    Enrollment open
    |
    BI 770371
    4ms
    A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BI 770371
    5ms
    Signal Transducer Nanoparticles Enable Siglec-10/G Blockade Immunotherapy for Breast Cancer Treatment. (PubMed, Adv Mater)
    The therapeutic effects can be further improved through encapsulation of RRx-001, a small molecule inhibitor of the CD47-SIRPα signaling. Compared to the antibody approach, the synthetic nanoparticle approach offers greater efficacy with lower side effects and enables combination therapy through a simple formulation. Moreover, the approach is versatile and could be adapted for targeting other ICB signaling, advancing the next generation of cancer immunotherapy.
    Journal
    |
    CD24 (CD24 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    nibrozetone (RRx-001)
    5ms
    A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=100, Completed, OSE Immunotherapeutics | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2025
    Trial completion • Trial completion date
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    ezabenlimab (BI 754091) • BI 765063
    6ms
    Biomimetic Delivery of Cisplatin for Efficient Immunotherapy of Gasdermin E-Positive Hepatocellular Carcinoma via a Pt Concentration-Dependent Minimalist Pyroptosis Strategy. (PubMed, Adv Healthc Mater)
    Compared to the classical Gasdermin D (GSDMD)-mediated pyroptosis that has been extensively explored for cancer immunotherapy, the direct induction of Gasdermin E (GSDME) pyroptosis has been rarely reported, likely due to the well-recognized reduced GSDME levels in solid tumors. This nanoplatform, CDDP/1-bromoacetyl-3,3-dinitroazetidine (RRx-001) @iRGD-Pla-Exo nanoparticles (CRRPE NPs) leads to almost complete tumor eradication in a Hepa1-6-luc orthotopic liver cancer model by activating macrophages, and can be combined with the commercially available programmed death ligand 1 (PD-L1) antibody immunomodulator to maintain T cells' effector function for a prolonged survival lifetime. Overall, this study provides a conceptual advance in revealing the role of chemotherapy in mediating tumor cell pyroptosis and immune cell activation.
    Journal
    |
    GSDME (Gasdermin E)
    |
    cisplatin • nibrozetone (RRx-001)
    6ms
    A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
    P1, N=13, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2026 --> Dec 2025
    Trial completion date
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    ezabenlimab (BI 754091) • BI 765063 • BI 770371
    6ms
    A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date
    |
    ezabenlimab (BI 754091) • BI 770371